Angiogenesis in multiple myeloma

被引：138

作者：

Jakob, Christian ^{[1
]}

Sterz, Jan ^{[1
]}

Zavrski, Ivana ^{[1
]}

Heider, Ulrike ^{[1
]}

Kleeberg, Lorenz ^{[1
]}

Fleissner, Claudia ^{[1
]}

Kaiser, Martin ^{[1
]}

Sezer, Orhan ^{[1
]}

机构：

[1] Univ Med Berlin, Charite, Dept Haematol & Oncol, D-10117 Berlin, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 11期

关键词：

multiple myeloma; angiogenesis; bone marrow; microenvironment; endothelial cells; cytokines; bFGF; VEGF; HGF;

D O I：

10.1016/j.ejca.2006.02.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) was the first haematological malignancy in which a prognostic relevance of bone marrow microvessel density (MVD) was shown. Myeloma-induced angiogenesis involves either the direct production of angiogenic molecules by myeloma cells or their induction in bone marrow stromal cells or endothelial cells (EC). Recent data demonstrate an increased angiogenic potential and a paracrine stimulatory effect of bone marrow EC on plasma cells (PC) in MM. Soluble angiogenic factors are elevated in bone marrow (BM) and in peripheral blood samples from myeloma patients. Furthermore, correlation with disease stage and prognosis was shown for serum levels of the angiogenic factors basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). In this review we summarize recent data which give strong evidence for an increased angiogenic activity in bone marrow microenvironment and support the hypothesis that angiogenesis is not only an epiphenomenon of tumour growth but may also promote PC growth in MM. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1581 / 1590

页数：10

共 112 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Bone marrow microvascular density and angiogenic growth factors in multiple myeloma [J].

Alexandrakis, MG ;

Passam, FJ ;

Ganotakis, E ;

Dafnis, E ;

Dambaki, C ;

Konsolas, J ;

Kyriakou, DS ;

Stathopoulos, E .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2004, 42 (10) :1122-1126

[3] Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival [J].

Andersen, NF ;

Standal, T ;

Nielsen, JL ;

Heickendorff, L ;

Borset, M ;

Sorensen, FB ;

Abildgaard, N .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (02) :210-217

[4]

Asosingh K, 2001, CANCER RES, V61, P2862

[5] Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology [J].

Banks, RE ;

Forbes, MA ;

Kinsey, SE ;

Stanley, A ;

Ingham, E ;

Walters, C ;

Selby, PJ .

BRITISH JOURNAL OF CANCER, 1998, 77 (06) :956-964

[6] Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells [J].

Barille, S ;

Akhoundi, C ;

Collette, M ;

Mellerin, MP ;

Rapp, MJ ;

Harousseau, JL ;

Bataille, R ;

Amiot, M .

BLOOD, 1997, 90 (04) :1649-1655

[7]

BATAILLE R, 1992, BLOOD, V80, P733

[8]

Bellamy WT, 1999, CANCER RES, V59, P728

[9] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[10] Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma [J].

Bertolini, F ;

Paolucci, M ;

Peccatori, F ;

Cinieri, S ;

Agazzi, A ;

Ferrucci, PF ;

Cocorocchio, E ;

Goldhirsch, A ;

Martinelli, G .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) :504-509

← 1 2 3 4 5 6 7 8 9 10 →